Translating Clinical Evidence forSensor-Based Glucose Monitoring and Technological Innovations to the Front Lines of Clinical Practice
Estimated Time to Complete Educational Activity
2 hour 20 minutes
In this web-based program, physicians will learn how recent developments in sensor-based continuous glucose monitoring have advanced the management of Type 1 and Type 2 diabetes.
June 13, 2020
June 13, 2022
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period June 13, 2020 to June 13, 2022 participants must:
1) read the learning objectives and faculty disclosures;
2) study the educational activity, and are expected to view all 6 segments totaling 2 hours to successfully complete the activity and earn CME credit;
3) register and complete the evaluation form and post-test;
4) score 100% on the post-test; and
5) print out your CME certificate.
Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Supported by an educational grant from Abbott.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physician.
Credit Designation Statement
The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
The University of Massachusetts Medical School requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to The University of Massachusetts Medical School policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCM.
Program Faculty and Disclosure
James R. Gavin III, MD, PhD
Chief Medical Officer
Healing Our Village, Inc.
Clinical Professor of Medicine
Emory University School of Medicine
Board Member/Advisory Panel: Abbott Diabetes Care; Janssen Pharmaceuticals; Merck; Novo Nordisk, Inc.; Intarcia Pharmaceuticals
Consultant: Boehringer Ingelheim/Lilly Alliance; Janssen Pharmaceuticals
Speaker’s Bureau: AstraZeneca; Boehringer Ingelheim/Lilly Alliance; Janssen Pharmaceuticals; Merck; Novo Nordisk, Inc.; Salix Pharmaceuticals
Irl Hirsch, MD
Professor of Medicine
Diabetes Treatment and Teaching Chair
University of Washington Medical Center
UWMC Diabetes Care Center
Seattle, Washington, USA
Research: Medtronic Diabetes, Insulet
Consultant: Abbott Diabetes Care, Bigfoot, Roche
Eden Miller, DO
Executive Director and Co?Founder
High Lakes Health Care
St. Charles Hospital
Bend, Oregon, USA
Advisor or consultant: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Becton, Dickinson and Company; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Lilly; Novo Nordisk; Sanofi Aventis
Speaker or Speakers Bureau: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly; Novo Nordisk
Richard Bergenstal, MD
International Diabetes Center- Park Nicollet
Minneapolis, MN, United States
Clinical Research, Scientific Advisory Board, and/or Consultant: Abbott Diabetes Care, Ascenia, CeQur, Dexcom, Eli Lilly, Hygieia, Johnson & Johnson, Medtronic, Novo Nordisk, Onduo, Roche, Sanofi, Senseonics and United Healthcare
Program Faculty and Disclosure
Program Manager Gideon Bosker, MD and Denise Leary have nothing to disclose.
Upon completion of the proposed program activities, physicians will be able to:
- Outline and discuss the evidentiary basis for senor/patch-based CGM technologies, and how to best Implement CGM-based technologies into their overall diabetes care plans for patients with T1D and T2D.
- Analyze the rationale and evidence for recommending and facilitating adoption of technology-centric CGM monitoring and treatment plans using patch-and-reader-based technologies.
- Compare and contrast available CGM-facilitating monitoring technologies and pair such technologies with optimal patient profiles.
- Educate patients with diabetes about the rationale, evidence, and outcome- optimizing results associated with technology-based, patient-centric and physician-directed CGM monitoring strategies that can be used to effect optimal lifestyle, diet-, and pharmacology-based approaches to attaining guideline-based HA1c levels in patients with T1d and T2D.
- Identify which patients with diabetes are ideal candidates for a technology-based, patient-directed glucose monitoring system.
- Interpret and apply data and results from clinical trials and experts with experience in CGM-facilitating monitoring technologies to improve patient care, improve safety of drug therapy for T1D and T2D, detect and mitigate risk of hypoglycemia, improve patient- and physician-directed changes in antidiabetic therapy, reinforce the safe use of antidiabetic drugs, and facilitate patient-activated drug titration, glycemic monitoring and disease management.
- Translate landmark clinical studies focused on CGM-based technologies to the front lines of clinical practice in the diabetes and primary care setting; and understand the translational implications of deploying sensor-based, CGM-based technologies as a foundational approach to improving outcomes in patients across the spectrum of diabetes.
- Educate other clinical providers on the diabetes care team about the rationale, role, evidence, and outcome-enhancing results that are derived from employing technology-based CGM strategies—both patient- and physician-directed—across the broad spectrum of patients with diabetes.
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
- We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
- For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
- We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
- If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.